Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Receivables (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Change in Receivables readings, the most recent being -$1.3 million for Q1 2026.

  • On a quarterly basis, Change in Receivables fell 116.95% to -$1.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$8.9 million, a 67.08% increase, with the full-year FY2025 number at -$229000.0, up 99.3% from a year prior.
  • Change in Receivables hit -$1.3 million in Q1 2026 for Atara Biotherapeutics, down from -$660000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $40.0 million in Q4 2022 to a low of -$39.8 million in Q1 2023.
  • Median Change in Receivables over the past 5 years was -$318000.0 (2022), compared with a mean of -$58000.0.
  • Biggest five-year swings in Change in Receivables: skyrocketed 454.84% in 2023 and later plummeted 30474.55% in 2024.
  • Atara Biotherapeutics' Change in Receivables stood at $40.0 million in 2022, then fell by 15.08% to $33.9 million in 2023, then crashed by 99.57% to $147000.0 in 2024, then plummeted by 548.98% to -$660000.0 in 2025, then tumbled by 89.85% to -$1.3 million in 2026.
  • The last three reported values for Change in Receivables were -$1.3 million (Q1 2026), -$660000.0 (Q4 2025), and $1.9 million (Q3 2025) per Business Quant data.